NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second closing was led by Fortune Fountain Capital and included an investment from Good Health Capital.
DiaCarta Founder and CEO Aiguo Zhang said in a statement that the financing will support continued development of the company’s core XNA technology platform, and will support work to expand its diagnostic products for non-invasive early detection and monitoring of cancers. This will include establishing global clinical study programs in various areas, the commercial launch of the firm's liquid biopsy ColoScape assay for the detection of colorectal cancer, and the inception of new product development pipelines.
Funds raised will also help support future marketing applications to the US and China Food and Drug Administrations for relevant tests, Zhang said.